Keros Therapeutics (KROS) said Tuesday that it will receive a $200 million upfront payment from Takeda Pharmaceutical (TAK) in connection to a global development and commercialization license deal to advance elritercept.
The license agreement with Takeda took effect on Jan. 16, the biopharmaceutical company said.
Keros shares were up 5% and Takeda shares were edging 0.3% higher in recent premarket activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.